Noninvasive Prenatal Testing

Mirvie RNA test aims to predict pregnancy complications

January 13, 2022

Maneesh Jain, CEO and co-founder of Mirvie, a proprietary RNA platform that uses blood samples to predict pregnancy complications such as preeclampsia, sits down with Contemporary OB/GYN to discuss the potential of the test.

Noninvasive prenatal screening for single-gene disorders

September 08, 2021

A study in the journal Ultrasound in Obstetrics & Gynecology1 has found that noninvasive prenatal testing (NIPT) can help in the early detection of a set of single gene disorders (SGDs), especially in the presence of either abnormal ultrasound findings or a family history.

Noninvasive prenatal testing and good motherhood

August 31, 2021

Pregnant women do not believe that noninvasive prenatal testing (NIPT) is an obligation of responsible motherhood, according to a qualitative study that investigated the impact of NIPT on women's moral beliefs about the meaning of prenatal screening.

NIPT may not be as effective for twin pregnancies

July 20, 2021

Clinicians should carefully consider using noninvasive prenatal testing (NIPT) for the screening of chromosomal abnormalities in twin pregnancies because the combined positive predictive value (PPV) is limited and the screening efficiency is not stable, according to a prospective study.

Risk of miscarriage with amniocentesis

July 19, 2021

Despite the inadvisability of performing early amniocentesis (EA) before 15 gestational weeks due to a high rate of miscarriage, a retrospective cohort study has found no significant difference in the procedure-related risk of miscarriage between EA, at around 14 weeks gestation, and mid-trimester amniocentesis (MA).

NIPT genome analysis for predicting cancer

June 21, 2021

A retrospective analysis has found that comprehensive examination of shallow-sequenced, whole-genome cell-free DNA (cfDNA) allows for the incidental detection of maternal tumors, with relatively high precision.

Whole genome sequencing of cell-free DNA for NIPT

May 05, 2021

An analysis of a large cohort of patients who chose noninvasive prenatal testing (NIPT) as a screening method for fetal trisomy 21, 18, and 13 (T21, T18 and T13) and sex chromosome aneuploidies (SCA) concluded there were extremely high detection rates and exceptionally low false positive rates.